Literature DB >> 12133934

Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR/CD3 pathway.

Mitsuru Matsumoto1, Takuji Yamada, Steven K Yoshinaga, Tom Boone, Tom Horan, Shigeru Fujita, Yi Li, Tasuku Mitani.   

Abstract

NF-kappa B-inducing kinase (NIK) is involved in lymphoid organogenesis in mice through lymphotoxin-beta receptor signaling. To clarify the roles of NIK in T cell activation through TCR/CD3 and costimulation pathways, we have studied the function of T cells from aly mice, a strain with mutant NIK. NIK mutant T cells showed impaired proliferation and IL-2 production in response to anti-CD3 stimulation, and these effects were caused by impaired NF-kappa B activity in both mature and immature T cells; the impaired NF-kappa B activity in mature T cells was also associated with the failure of maintenance of activated NF-kappa B. In contrast, responses to costimulatory signals were largely retained in aly mice, suggesting that NIK is not uniquely coupled to the costimulatory pathways. When NIK mutant T cells were stimulated in the presence of a protein kinase C (PKC) inhibitor, proliferative responses were abrogated more severely than in control mice, suggesting that both NIK and PKC control T cell activation in a cooperative manner. We also demonstrated that NIK and PKC are involved in distinct NF-kappa B activation pathways downstream of TCR/CD3. These results suggest critical roles for NIK in setting the threshold for T cell activation, and partly account for the immunodeficiency in aly mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133934     DOI: 10.4049/jimmunol.169.3.1151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells.

Authors:  Ann J McPherson; Laura M Snell; Tak W Mak; Tania H Watts
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

Review 2.  RelB: an outlier in leukocyte biology.

Authors:  Patrick Millet; Charles McCall; Barbra Yoza
Journal:  J Leukoc Biol       Date:  2013-08-06       Impact factor: 4.962

3.  NIK prevents the development of hypereosinophilic syndrome-like disease in mice independent of IKKα activation.

Authors:  Hans Häcker; Liying Chi; Jerold E Rehg; Vanessa Redecke
Journal:  J Immunol       Date:  2012-04-02       Impact factor: 5.422

4.  Significant involvement of nuclear factor-κB-inducing kinase in proper differentiation of αβ and γδ T cells.

Authors:  Koji Eshima; Motohito Okabe; Satoshi Kajiura; Haruka Noma; Nobukata Shinohara; Kazuya Iwabuchi
Journal:  Immunology       Date:  2014-02       Impact factor: 7.397

Review 5.  The noncanonical NF-κB pathway.

Authors:  Shao-Cong Sun
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 6.  NF-κB inducing kinase: a key regulator in the immune system and in cancer.

Authors:  Yee Mon Thu; Ann Richmond
Journal:  Cytokine Growth Factor Rev       Date:  2010-08-03       Impact factor: 7.638

7.  A cell-intrinsic requirement for NF-κB-inducing kinase in CD4 and CD8 T cell memory.

Authors:  Alexander M Rowe; Susan E Murray; Hans-Peter Raué; Yoshinobu Koguchi; Mark K Slifka; David C Parker
Journal:  J Immunol       Date:  2013-09-04       Impact factor: 5.422

8.  NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis.

Authors:  Kunihiko Aya; Muhammad Alhawagri; Amanda Hagen-Stapleton; Hideki Kitaura; Osami Kanagawa; Deborah Veis Novack
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

9.  The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma.

Authors:  Yang-Seon Yi; Joo-Seop Chung; Moo-Kon Song; Ho-Jin Shin; Young-Mi Seol; Young-Jin Choi; Goon-Jae Cho; Gyeong-Won Lee; Joon-Ho Moon; In-Hye Hwang; Kang-Hee Ahn; Hee-Sun Lee; Kyung-Hwa Shin; Jong-Min Hwang
Journal:  Korean J Hematol       Date:  2010-09-30

10.  Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.

Authors:  Sung-Hoon Jung; Soo-Young Bae; Jae-Sook Ahn; Seung-Ji Kang; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Int J Hematol       Date:  2013-01-25       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.